Showing 291-300 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Low-dose IL-2 and anti-CD40L as a therapy for type 1 diabetes | University of Miami | Thomas Malek | Cures | 01-June-2024 to 31-May-2027 | $927.000,00 |
| CD40L-Targeting Small Molecules as Novel Immunotherapies in Islet Cell Transplantation and T1D Prevention | University of Miami | Peter Buchwald | Cures | 01-October-2026 to 30-September-2027 | $250.000,00 |
| Enhance β-Cell Replacement Therapies via Localized Immune Modulation Using DIANA Nanocarriers | University of Miami | Peter Buchwald | Cures | 01-September-2023 to 31-August-2026 | $900.000,00 |
| bifunctional RNA therapeutics for T1D | University of Miami | Paolo Serafini | Cures | 01-February-2025 to 31-January-2028 | $900.000,00 |
| Modulate beta cell proliferation and immunogenicity via aptamer-decorated lipid nanoparticles | University of Miami | Paolo Serafini | Cures | 01-April-2023 to 31-March-2027 | $894.602,00 |
| Role of pericytes during type 1 diabetes pathogenesis | University of Miami | Luciana Mateus Goncalves | Cures | 01-March-2024 to 28-February-2027 | $259.750,00 |
| Preclinical development of the BMP receptor agonist THR-184 for beta cell regeneration | University of Miami | Juan Dominguez-Bendala | Cures | 01-April-2024 to 31-March-2027 | $741.000,00 |
| Safety, Feasibility, and Mechanistic Effects of Diroximel Fumarate (DRF) in New-Onset Type 1 Diabetes. | University of Miami | Francesco Vendrame | Cures | 01-August-2026 to 31-July-2029 | $698.164,00 |
| The KQ1 serum study: amendment & extension | University of Miami | Dirk Homann | Cures | 01-April-2025 to 31-October-2027 | $1.723.254,07 |
| Towards an integrated proteomic and transcriptomic single-cell atlas of the human pancreas | University of Miami | Dirk Homann | Cures | 01-April-2025 to 31-March-2027 | $53.972,92 |